REFERENCES
1. Simon TA, Kawabata H, Ray N, Baheti A, Suissa S, Esdaile JM. Prevalence of co-existing autoimmune disease in rheumatoid arthritis: a cross-sectional study. Adv Ther 2017;34:2481-90.
2. Chen W, Wang Q, Zhou B, et al. Lipid metabolism profiles in rheumatic diseases. Front Pharmacol 2021;12:443.
3. Rhoads JP, Major AS, Rathmell JC. Fine tuning of immunometabolism for the treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13:313-20.
4. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta. Clin Dev Immunol 2012;2012:832464.
5. Cleeman JI. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum 2016;45:604-10.
7. Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune rheumatic diseases and vascular function: the concept of autoimmune atherosclerosis. J Clin Med 2021;10:4427.
9. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018;361:k1036.
10. Sobenin IA, Sazonova MA, Postnov AY, Salonen JT, Bobryshev YV, Orekhov AN. Association of mitochondrial genetic variation with carotid atherosclerosis. PLoS One 2013;8:e68070.
11. Schwartz DM, Burma AM, Kitakule MM, Luo Y, Mehta NN. T Cells in autoimmunity-associated cardiovascular diseases. Front Immunol 2020;11:588776.
12. Sobenin IA, Mitrofanov KY, Zhelankin AV, et al. Quantitative assessment of heteroplasmy of mitochondrial genome: perspectives in diagnostics and methodological pitfalls. Biomed Res Int 2014;2014:292017.
14. Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 2020;16:19-30.
15. Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol 2020;18:549-65.
16. Samuelsson I, Parodis I, Gunnarsson I, et al. Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. Lupus Sci Med 2021;8:e000515.
17. Ryu H, Kim J, Kim D, Lee JE, Chung Y. Cellular and molecular links between autoimmunity and lipid metabolism. Mol Cells 2019;42:747-54.
18. Kobiyama K, Ley K. Atherosclerosis: a chronic inflammatory disease with an autoimmune component. Circ Res 2018;123:1118-20.
19. Sobenin IA. Atherogenesis, atherosclerosis and related diseases: unresolved issues. Vessel Plus 2020;4:18.
20. Summerhill VI, Grechko AV, Yet SF, Sobenin IA, Orekhov AN. The atherogenic role of circulating modified lipids in atherosclerosis. Int J Mol Sci 2019;20:3561.
21. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 2016;118:547-63.
22. Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A. Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmun Rev 2017;16:308-12.
23. Chistiakov DA, Sobenin IA, Orekhov AN. Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv 2012;19:392-405.
24. Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res 2019;124:1505-18.
25. Goldberg IJ, Reue K, Abumrad NA, et al. Deciphering the role of lipid droplets in cardiovascular disease: a report from the 2017 national heart, lung, and blood institute workshop. Circulation 2018;138:305-15.
26. Brown MS, Goldstein JL, Krieger M, Ho YK, Anderson RG. Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol 1979;82:597-613.
27. Guo S, Li L, Yin H. Cholesterol homeostasis and liver X receptor (LXR) in atherosclerosis. Cardiovasc Hematol Disord Drug Targets 2018;18:27-33.
28. Yu XH, Tang CK. ABCA1, ABCG1, and cholesterol homeostasis. Adv Experimental Med Biol 2022;1377:95-107.
29. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res 2018;114:540-50.
30. Chen W, Li L, Wang J, et al. The ABCA1-efferocytosis axis: a new strategy to protect against atherosclerosis. Clin Chim Acta 2021;518:1-8.
31. Skarda L, Kowal J, Locher KP. Structure of the human cholesterol transporter ABCG1. J Mol Biol 2021;433:167218.
32. Wróblewska M. The origin and metabolism of a nascent pre-β high density lipoprotein involved in cellular cholesterol efflux. Acta Biochim Pol 2011;58:275-85.
33. Shen WJ, Azhar S, Kraemer FB. SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. Annu Rev Physiol 2018;80:95-116.
34. Madison BB. Srebp2: a master regulator of sterol and fatty acid synthesis. J Lipid Res 2016;57:333-5.
35. Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol 2018;14:452-63.
36. Hua X, Yokoyama C, Wu J, et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 1993;90:11603-7.
37. Kong M, Zhu Y, Shao J, Fan Z, Xu Y. The chromatin remodeling protein BRG1 regulates SREBP maturation by activating SCAP transcription in hepatocytes. Front Cell Dev Biol 2021;9:622866.
38. Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther 2022;7:265.
39. Guo C, Chi Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 2018;49:842-856.e7.
40. Brown MS, Radhakrishnan A, Goldstein JL. Retrospective on cholesterol homeostasis: the central role of scap. Annu Rev Biochem 2018;87:783-807.
41. He C, Hu X, Weston TA, et al. Macrophages release plasma membrane-derived particles rich in accessible cholesterol. Proc Natl Acad Sci USA 2018;115:E8499-508.
42. Hafiane A, Genest J. ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. Atherosclerosis 2017;257:90-9.
43. Ong DS, Anzinger JJ, Leyva FJ, Rubin N, Addadi L, Kruth HS. Extracellular cholesterol-rich microdomains generated by human macrophages and their potential function in reverse cholesterol transport. J Lipid Res 2010;51:2303-13.
44. Jin X, Dimitriadis EK, Liu Y, et al. Macrophages shed excess cholesterol in unique extracellular structures containing cholesterol microdomains. Arterioscler Thromb Vasc Biol 2018;38:1504-18.
45. He C, Hu X, Weston TA, et al. Macrophages release plasma membrane-derived particles rich in accessible cholesterol. Proc Natl Acad Sci USA 2018;115:E8499-508.
46. Hu X, Weston TA, He C, et al. Release of cholesterol-rich particles from the macrophage plasma membrane during movement of filopodia and lamellipodia. Elife 2019;8:e50231.
47. He C, Jiang H, Song W, et al. Cultured macrophages transfer surplus cholesterol into adjacent cells in the absence of serum or high-density lipoproteins. Proc Natl Acad Sci USA 2020;117:10476-83.
48. Dupont M, Souriant S, Lugo-Villarino G, Maridonneau-Parini I, Vérollet C. Tunneling nanotubes: intimate communication between myeloid cells. Front Immunol 2018;9:43.
49. Kentala H, Weber-Boyvat M, Olkkonen VM. OSBP-related protein family: mediators of lipid transport and signaling at membrane contact sites. Int Rev Cell Mol Biol 2016;321:299-340.
50. Ouimet M, Hennessy EJ, van Solingen C, et al. miRNA targeting of oxysterol-binding protein-like 6 regulates cholesterol trafficking and efflux. Arterioscler Thromb Vasc Biol 2016;36:942-51.
51. Schulman IG. Liver X receptors link lipid metabolism and inflammation. FEBS Lett 2017;591:2978-91.
52. Endo-Umeda K, Kim E, Thomas DG, et al. Myeloid LXR (liver X receptor) deficiency induces inflammatory gene expression in foamy macrophages and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 2022;42:719-31.
53. Teupser D, Kretzschmar D, Tennert C, et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008;28:2009-15.
54. Savla SR, Prabhavalkar KS, Bhatt LK. Liver X receptor: a potential target in the treatment of atherosclerosis. Expert Opin Ther Targets 2022;26:645-58.
55. Saliba-Gustafsson P, Pedrelli M, Gertow K, et al. Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy. J Intern Med 2019;286:660-75.
56. Groh L, Keating ST, Joosten LAB, Netea MG, Riksen NP. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol 2018;40:203-14.
57. Bes C, Gürel S, Buğdaycı G, Dikbaş O, Soy M. Atherosclerosis assessment and rheumatoid arthritis. Z Rheumatol 2018;77:330-4.
58. Kraakman MJ, Dragoljevic D, Kammoun HL, Murphy AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Clin Transl Immunology 2016;5:e84.
59. Hirose S, Lin Q, Ohtsuji M, Nishimura H, Verbeek JS. Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol 2019;31:687-96.
60. Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton JA. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther 2016;18:287.
61. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121:4138-49.
62. Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, et al. Differences in capacity of high-density lipoprotein cholesterol efflux between patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 2021;73:1590-6.
63. Ormseth MJ, Yancey PG, Yamamoto S, et al. Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. IJC Metab Endocr 2016;13:6-11.
64. Xie B, He J, Liu Y, Liu T, Liu C. A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis. Lipids Health Dis 2021;20:18.
65. Nowak B, Madej M, Łuczak A, Małecki R, Wiland P. Disease activity, oxidized-LDL fraction and anti-oxidized LDL antibodies influence cardiovascular risk in rheumatoid arthritis. Adv Clin Exp Med 2016;25:43-50.
66. Westerterp M, Tsuchiya K, Tattersall IW, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in endothelial cells accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2016;36:1328-37.
67. Hannawi S, Hannawi H, Al Salmi I. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis. Hypertens Res 2020;43:982-4.
68. Dragoljevic D, Kraakman MJ, Nagareddy PR, et al. Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis. Eur Heart J 2018;39:2158-67.
69. Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012;71:1157-62.
70. Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys 2018;640:47-52.
71. Frangie C, Daher J. Role of myeloperoxidase in inflammation and atherosclerosis (Review). Biomed Rep 2022;16:53.
72. Ndrepepa G. Myeloperoxidase - a bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta 2019;493:36-51.
73. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41.
74. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38:372-81.
75. MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: fuelling the Fire of atherosclerosis or therapeutic extinguishers? Int J Mol Sci 2021;22:7622.
76. Liu T, Shi N, Zhang S, et al. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. Lupus 2020;29:273-82.
77. Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus 2014;23:1546-52.
78. Chiesa ST, Charakida M. High-density lipoprotein function and dysfunction in health and disease. Cardiovasc Drugs Ther 2019;33:207-19.
79. Wang Y, Yu H, He J. Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases. Discov Med 2020;30:49-56.
80. Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A. High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheumatol 2020;72:20-30.
81. Aguilar-Ballester M, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, González-Navarro H. Impact of cholesterol metabolism in immune cell function and atherosclerosis. Nutrients 2020;12:2021.
82. Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res 2017;65:543-50.
83. Shridas P, Tannock LR. Role of serum amyloid A in atherosclerosis. Curr Opin Lipidol 2019;30:320-5.
84. Jin Z, Zhou L, Tian R, Lu N. Myeloperoxidase targets apolipoprotein A-I for site-specific tyrosine chlorination in atherosclerotic lesions and generates dysfunctional high-density lipoprotein. Chem Res Toxicol 2021;34:1672-80.
85. Witkowski A, Chan GKL, Boatz JC, et al. Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation. FASEB J 2018;32:3149-65.
86. Xepapadaki E, Zvintzou E, Kalogeropoulou C, Filou S, Kypreos KE. Τhe antioxidant function of HDL in atherosclerosis. Angiology 2020;71:112-21.
87. De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014;15:152-60.
88. Yin K, Chen WJ, Zhou ZG, et al. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb 2012;19:823-36.
89. Parra S, Vives G, Ferré R, et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis 2012;225:224-30.
90. Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. Clin Immunol 2010;137:147-56.
91. Markin A, Markina Y, Sukhorukov V, et al. The role of physical activity in the development of atherosclerotic lesions of the vascular wall. Clin Exp Morphol 2019;8:25-31.
92. Smith CK, Seto NL, Vivekanandan-Giri A, et al. Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Ann Rheum Dis 2017;76:602-11.
94. Lewis MJ, Malik TH, Fossati-Jimack L, et al. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum 2012;64:2707-18.
95. Robinson G, Pineda-Torra I, Ciurtin C, Jury EC. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J Clin Invest 2022;132:e148552.
96. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol 2015;15:511-23.
97. Howie D, Ten Bokum A, Necula AS, Cobbold SP, Waldmann H. The role of lipid metabolism in T lymphocyte differentiation and survival. Front Immunol 2017;8:1949.
98. Zhornitsky S, McKay KA, Metz LM, Teunissen CE, Rangachari M. Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Mult Scler Relat Disord 2016;5:53-65.
99. Sun W, Li P, Cai J, et al. Lipid metabolism: immune regulation and therapeutic prospectives in systemic lupus erythematosus. Front Immunol 2022;13:1154.
100. Shih CM, Chen CC, Chu CK, Wang KH, Huang CY, Lee AW. The roles of lipoprotein in psoriasis. Int J Mol Sci 2020;21:859.
101. Nowowiejska J, Baran A, Flisiak I. Aberrations in lipid expression and metabolism in psoriasis. Int J Mol Sci 2021;22:6561.
102. Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther 2020;37:2017-33.
103. Ramezani M, Zavattaro E, Sadeghi M. Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta-analysis of case-control studies. Postepy Dermatol Alergol 2019;36:692-702.
104. Miller IM, Skaaby T, Ellervik C, Jemec GB. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol 2013;169:1180-7.
105. Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 2012;53:1618-24.
106. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-61.
107. Yang H, Zhang N, Okoro EU, Guo Z. Transport of apolipoprotein B-containing lipoproteins through endothelial cells is associated with apolipoprotein E-carrying HDL-like particle formation. Int J Mol Sci 2018;19:3593.
108. Tiwari S, Siddiqi SA. Intracellular trafficking and secretion of very low density lipoproteins. Arterioscler Thromb Vasc Biol 2012;32:1079-86.
109. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008;18:228-32.
110. Frambach SJCM, de Haas R, Smeitink JAM, Rongen GA, Russel FGM, Schirris TJJ. Brothers in arms: ABCA1- and ABCG1-Mediated cholesterol efflux as promising targets in cardiovascular disease treatment. Pharmacol Rev 2020;72:152-90.
112. Soldatov VO, Malorodova TN, Pokrovskaya TG, et al. Ultrasonic dopplerography for the evaluation of endothelial function in the conduct of pharmacological vascular samples in an experiment Production and Hosted by. Int J Res Pharm Sci 2018;9:735-40.
113. Filippi MD. Mechanism of diapedesis: importance of the transcellular route. Adv Immunol 2016;129:25-53.
114. Soldatov VO, Malorodova TN, Balamutova TI, Ksenofontov AO, Dovgan AP, Urozhevskaya ZS. Endothelial dysfunction: comparative evaluation of ultrasound dopplerography, laser dopplerflowmetry and direct monitoring of arterial pressure for conducting pharmacological tests in rats. Res Results Pharmacol 2018;4:73-80.
115. Liberale L, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherogenesis. Thromb Haemost 2017;117:7-18.
116. Chistiakov DA, Orekhov AN, Sobenin IA, Bobryshev YV. Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. Front Physiol 2014;5:279.
117. Orekhov AN, Myasoedova VA. Low density lipoprotein-induced lipid accumulation is a key phenomenon of atherogenesis at the arterial cell level. Vessel Plus 2019;3:3.
118. Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Myeloid dendritic cells: development, functions, and role in atherosclerotic inflammation. Immunobiology 2015;220:833-44.
119. Yan J, Horng T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol 2020;30:979-89.
120. Paukner K, Králová Lesná I, Poledne R. Cholesterol in the cell membrane-an emerging player in atherogenesis. Int J Mol Sci 2022;23:533.
121. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40.
122. Boucher P, Matz RL, Terrand J. atherosclerosis: gone with the Wnt? Atherosclerosis 2020;301:15-22.
123. Groenen AG, Halmos B, Tall AR, Westerterp M. Cholesterol efflux pathways, inflammation, and atherosclerosis. Crit Rev Biochem Mol Biol 2021;56:426-39.
124. Ikonen E, Zhou X. Cholesterol transport between cellular membranes: a balancing act between interconnected lipid fluxes. Dev Cell 2021;56:1430-6.
125. Kim KW, Ivanov S, Williams JW. Monocyte recruitment, specification, and function in atherosclerosis. Cells 2020;10:15.
126. Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis, and atherothrombosis. Mediators Inflamm 2019;2019:7434376.
127. Baidžajevas K, Hadadi É, Lee B, et al. Macrophage polarisation associated with atherosclerosis differentially affects their capacity to handle lipids. Atherosclerosis 2020;305:10-8.
128. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150:1687.
129. Manjarrez-Reyna AN, Martínez-Reyes CP, Aguayo-Guerrero JA, et al. Native low-density lipoproteins act in synergy with lipopolysaccharide to alter the balance of human monocyte subsets and their ability to produce IL-1 beta, CCR2, and CX3CR1 in vitro and in vivo: implications in atherogenesis. Biomolecules 2021;11:1169.
130. Chistiakov DA, Revin VV, Sobenin IA, Orekhov AN, Bobryshev YV. Vascular endothelium: functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function. Mini Rev Med Chem 2015;15:338-50.
131. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease. Atherosclerosis 2013;227:283-8.
132. Yang S, Yuan HQ, Hao YM, et al. Macrophage polarization in atherosclerosis. Clin Chim Acta 2020;501:142-6.
133. Dhawan UK, Singhal A, Subramanian M. Dead cell and debris clearance in the atherosclerotic plaque: Mechanisms and therapeutic opportunities to promote inflammation resolution. Pharmacol Res 2021;170:105699.
134. Shklover J, Levy-Adam F, Kurant E. Apoptotic cell clearance in development. Curr Top Dev Biol 2015;114:297-334.
135. Zhao Y, Zhang L, Liu L, et al. Specific loss of ABCA1 (ATP-binding cassette transporter A1) suppresses TCR (T-cell receptor) signaling and provides protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2022;42:e311-26.
136. Wanke F, Gutbier S, Rümmelin A, et al. Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages. Cell Death Dis 2021;12:538.
137. Ruotsalainen AK, Lappalainen JP, Heiskanen E, et al. Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice. Cardiovasc Res 2019;115:243-54.
138. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003;23:1553-8.
139. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-8.
140. Orekhov AN, Orekhova VA, Nikiforov NG, et al. Monocyte differentiation and macrophage polarization. Vessel Plus 2019;3:10.
141. Hanna RN, Carlin LM, Hubbeling HG, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol 2011;12:778-85.
142. Tang RZ, Zhu JJ, Yang FF, et al. DNA methyltransferase 1 and Krüppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis. J Mol Cell Cardiol 2019;128:11-24.
143. Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med 2012;4:1072-86.
144. Mushenkova NV, Nikiforov NG, Melnichenko AA, et al. Functional phenotypes of intraplaque macrophages and their distinct roles in atherosclerosis development and atheroinflammation. Biomedicines 2022;10:452.
145. Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 2010;107:737-46.
146. Jinnouchi H, Guo L, Sakamoto A, et al. Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci 2020;77:1919-32.
147. Nordlohne J, von Vietinghoff S. Interleukin 17A in atherosclerosis - regulation and pathophysiologic effector function. Cytokine 2019;122:154089.
148. Yao SY, Shen ML, Li SJ, et al. Application of a mechanically responsive, inflammatory macrophage-targeted dual-sensitive hydrogel drug carrier for atherosclerosis. Colloids Surf B Biointerfaces 2020;186:110718.
149. Chen X, Li X, Chen Q. Experimental study of ultrafine superparamagnetic iron oxide-enhanced MRI in an atherosclerotic plaque model. J Nanosci Nanotechnol 2020;20:7444-50.
150. Li Y, Pan Y, Wu X, et al. Dual-modality imaging of atherosclerotic plaques using ultrasmall superparamagnetic iron oxide labeled with rhodamine. Nanomedicine 2019;14:1935-44.
151. Nahrendorf M, Hoyer FF, Meerwaldt AE, et al. Imaging Cardiovascular and lung macrophages with the positron emission tomography sensor 64Cu-macrin in mice, rabbits, and pigs. Circ Cardiovasc Imaging 2020;13:e010586.
152. Konishi T, Norikane T, Yamamoto Y, et al. The potential relationship between 18F-FDG uptake and wall shear stress in a patient with carotid artery disease. J Nucl Cardiol 2021;28:367-70.
153. Fujimura Y, Hwang PM, Trout Iii H, et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis 2008;201:108-11.
154. Han S, Wang W, Wang S, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics 2021;11:2892-916.
155. Taghizadeh E, Taheri F, Renani PG, Reiner Ž, Navashenaq JG, Sahebkar A. Macrophage: a key therapeutic target in atherosclerosis? Curr Pharm Des 2019;25:3165-74.
156. Hetherington I, Totary-Jain H. Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations. Mol Ther 2022;30:3106-17.
157. Kang MK, Kim CJ, Choo EH, et al. Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET/CT imaging study. Int J Cardiovasc Imaging 2019;35:1745-53.
158. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-8.
